Tai chi for overweight/obese adolescent and young women with polycystic ovary syndrome: study protocol for a randomized controlled trial

Yan Li, Changle Peng, Guangying Cao, Wei Li, Lihui Hou, Yan Li, Changle Peng, Guangying Cao, Wei Li, Lihui Hou

Abstract

Background: Tai Chi is a moderately intense exercise that dates back to ancient China. It has been reported that Tai Chi not only has beneficial effects on metabolic disorders, such as diabetes, cardiovascular diseases and obesity, but also has favorable effects on psychological well-being. Since these conditions are quite closely associated with polycystic ovary syndrome (PCOS), we hypothesis that Tai Chi could be a potential treatment option for PCOS patients. We aim to determine the feasibility and effectiveness of Tai Chi on overweight/obese adolescent and young women with PCOS.

Methods: A total of 50 patients will be randomized into two arms: (1) Tai Chi or (2) self-monitored exercise. Both groups will exercise for 3 months. The primary hypothesis is that Tai Chi results in a significantly lower Body Mass Index (BMI) than self-monitored exercise. The study was approved by the Ethics Committee of the First Affiliated Hospital of Heilongjiang University of Chinese Medicine.

Discussion: This is the first study to determine the feasibility and effectiveness of Tai Chi in treating overweight/obese adolescent and young women with PCOS. The trial will provide evidence to assess the feasibility of a future multicenter, randomized controlled trial.

Trial registration: ClinicalTrials.gov, ID: NCT02608554 . Registered on 17 November 2015.

Keywords: Complementary and alternative medicine; Polycystic ovary syndrome; Tai chi.

Conflict of interest statement

Ethics approval and consent to participate

The present study received approval from the First Affiliated Hospital of Heilongjiang University of Chinese Medicine Institutional Review Boards (approval number HZYLLKT201500201).Written informed consent will be obtained from all patients prior to trial participation.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Study design flowchart
Fig. 2
Fig. 2
Schedule of enrollment, interventions and assessments (Additional file 1). Safety eligibility includes liver function, renal function and complete blood count (CBC). t1, 1 month after allocation; t2, 2 months after allocation; t3, 3 months after allocation, t4, the beginning of the 4th month after allocation

References

    1. Azziz R, Carmina E, Chen Z, Dunaif A, Laven JS, Legro RS, Lizneva D, Natterson-Horowtiz B, Teede HJ, Yildiz BO. Polycystic ovary syndrome. Nat Rev Dis Primers. 2016;11(2):16057. doi: 10.1038/nrdp.2016.57.
    1. Ehrmann DA. Polycystic ovary syndrome. N Engl J Med. 2005;352(12):1223–1236. doi: 10.1056/NEJMra041536.
    1. Orio F, Palomba S. Reproductive endocrinology: new guidelines for the diagnosis and treatment of PCOS. Nat Rev Endocrinol. 2014;10(3):130–132. doi: 10.1038/nrendo.2013.248.
    1. World Health Organisation, International Association for the Study of Obesity, International Obesity Task Force . The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne: Health communications, Australia Pty Ltd.; 2000.
    1. Barlow SE. Expert committee recommendations regarding the prevention, assessment, and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(Suppl 4):S164–S192. doi: 10.1542/peds.2007-2329C.
    1. Lim SS, Davies MJ, Norman RJ, Moran LJ. Overweight, obesity and central obesity in women with polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2012;18(6):618–637. doi: 10.1093/humupd/dms030.
    1. Bu Z, Dai W, Guo Y, Su Y, Zhai J, Sun Y. Overweight and obesity adversely affect outcomes of assisted reproductive technologies in polycystic ovary syndrome patients. Int J Clin Exp Med. 2013;6(10):991–995.
    1. Huang K, Liao X, Dong X, Zhang H. Effect of overweight/obesity on IVF-ET outcomes in Chinese patients with polycystic ovary syndrome. Int J Clin Exp Med. 2014;7(12):5872–5876.
    1. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocr Pract. 2015;21(11):1291–1300. doi: 10.4158/EP15748.DSC.
    1. Goodman NF, Cobin RH, Futterweit W, Glueck JS, Legro RS, Carmina E, et al. American Association of Clinical Endocrinologists, American College of Endocrinology, and Androgen Excess and PCOS Society Disease State Clinical Review: guide to the best practices in the evaluation and treatment of polycystic ovary syndrome—part 1. Endocr Pract. 2015;21(12):1415–1426. doi: 10.4158/EP15748.DSCPT2.
    1. Gateva A, Unfer V, Kamenov Z. The use of inositol(s) isomers in the management of polycystic ovary syndrome: a comprehensive review. Gynecol Endocrinol. 2018;34(7):545–550. doi: 10.1080/09513590.2017.1421632.
    1. Seyam E, Al Gelany S, Abd Al Ghaney A, Mohamed MAA, Youseff AM, Ibrahim EM, Khalifa EM, Hefzy E. Evaluation of prolonged use of statins on the clinical and biochemical abnormalities and ovulation dysfunction in single young women with polycystic ovary syndrome. Gynecol Endocrinol. 2018;34(7):589–596. doi: 10.1080/09513590.2017.1418853.
    1. Chen Y, Wang XJ, Jin HL, Jin L. Effects of resolving method of Chinese medicine on the lipid metabolism in polycystic ovary syndrome accompanied with non-alcoholic fatty liver disease. Zhongguo Zhong Xi Yi Jie He Za Zhi. 2013;33(6):751–756.
    1. Yang J, Liu Y, Huang J, Xu J, You X, Lin Q, Zhang J, Dun J, Huang S. Acupuncture and Chinese medicine of artificial cycle therapy for insulin resistance of polycystic ovary syndrome with phlegm damp type and its mechanism. Zhongguo Zhen Jiu. 2017;37(11):1163–1168.
    1. Zhuo D. Preventive geriatrics: an overview from traditional Chinese medicine. Am J Chin Med. 1982;10(1–4):32–39. doi: 10.1142/S0192415X82000063.
    1. Sun J, Buys N. Community-based mind-body meditative Tai Chi program and its effects on improvement of blood pressure, weight, renal function, serum lipoprotein, and quality of life in Chinese adults with hypertension. Am J Cardiol. 2015;116(7):1076–1081. doi: 10.1016/j.amjcard.2015.07.012.
    1. Hartley L, Flowers N, Lee MS, Ernst E, Rees K. Tai chi for primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2014;9(4):CD010366.
    1. Tsang T, Orr R, Lam P, Comino E, Singh MF. Effects of tai chi on glucose homeostasis and insulin sensitivity in older adults with type 2 diabetes: a randomized double-blind sham-exercise-controlled trial. Age Ageing. 2008;37(1):64–71. doi: 10.1093/ageing/afm127.
    1. Shayya R, Chang RJ. Reproductive endocrinology of adolescent polycystic ovary syndrome. BJOG. 2010;117:150–155. doi: 10.1111/j.1471-0528.2009.02421.x.
    1. Zhao X, Ni R, Li L, Mo Y, Huang J, Huang M, et al. Defining hirsutism in Chinese women: a cross-sectional study. FertilSteril. 2011;96(3):792–796.
    1. Hui SS, Xie YJ, Woo J, Kwok TC. Effects of Tai Chi and walking exercises on weight loss, metabolic syndrome parameters, and bone mineral density: a cluster randomized controlled trial. Evid Based Complement Alternat Med. 2015;2015:976123. doi: 10.1155/2015/976123.
    1. Johanson GA, Brooks GP. Initial scale development: sample size for pilot studies. EducPsychol Meas. 2010;70(3):394–400. doi: 10.1177/0013164409355692.
    1. Lin CY, Ou HT, Wu MH, Chen PC. Validation of Chinese version of Polycystic Ovary Syndrome Health-Related Quality of Life Questionnaire (Chi-PCOSQ) PLoS One. 2016;11(4):e0154343. doi: 10.1371/journal.pone.0154343.

Source: PubMed

Sponsor e collaboratori

Condizioni mediche

Interventi farmacologici

3
Sottoscrivi